Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC-ACI
- Development stage
- Preclinical
- Lead developer
- Medlab Group
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Sublingual
01
Overview
NC-ACI is a preclinical drug candidate being developed by Medlab Clinical (now Medlab Group) for the treatment of sarcopenia and the promotion of cellular biogenesis. The product utilizes Medlab's proprietary NanoCelle® technology, a sublingual nanoparticle delivery system that creates micellar structures to enhance the solubility and absorption of active pharmaceutical ingredients. NC-ACI consists of a repurposed generic pharmaceutical agent, the identity of which remains undisclosed, formulated for sublingual administration to trigger anabolic pathways and support cellular health in aging populations.
Beyond the preview
Go deeper on NC-ACI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC-ACI.